T4090 vs Rhopressa for Glaucoma

Phase 2

Waitlist Available

Research Sponsored by Laboratoires Thea

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient (male or female) ≥18 years old

Patient with Open Angle Glaucoma or Ocular Hypertension in both eyes

Must not have

Secondary Open Angle Glaucoma (ex. Pseudoexfoliation, Pigmentary glaucoma)

Advanced stage of glaucoma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up the primary efficacy endpoint is the change from baseline (d1) at week 7 in the mean diurnal iop in the study eye.

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to compare the effectiveness and safety of two different concentrations of T4090 eye drops (0.2% and 0.3%) with Rhopressa® eye drops in reducing

Who is the study for?

This trial is for adults over 18 with Open-Angle Glaucoma or Ocular Hypertension in both eyes. Participants must understand the study and sign a consent form.

What is being tested?

The trial aims to compare the effectiveness and safety of two concentrations (0.2% and 0.3%) of T4090 ophthalmic solution against Rhopressa® in reducing eye pressure.

What are the potential side effects?

Potential side effects may include mild to moderate eye irritation, redness, discomfort, or blurred vision similar to other glaucoma medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with glaucoma or high eye pressure in both eyes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a specific type of glaucoma not caused by an eye injury.

Select...

My glaucoma is in an advanced stage.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ the primary efficacy endpoint is the change from baseline (d1) at week 7 in the mean diurnal iop in the study eye.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~the primary efficacy endpoint is the change from baseline (d1) at week 7 in the mean diurnal iop in the study eye.

This trial's timeline: 3 weeks for screening, Varies for treatment, and the primary efficacy endpoint is the change from baseline (d1) at week 7 in the mean diurnal iop in the study eye. for reporting.